We are live on ! Find out more
SCLN

Sciclone Pharmaceuticals Inc
SCLN

Delisted

SCLN was delisted on the 13th of October, 2017.

Back to rankings

96 hedge funds and large institutions have $122M invested in Sciclone Pharmaceuticals Inc in 2014 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 33 increasing their positions, 40 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

4% less funds holding

Funds holding: 100 → 96 (-4)

14% less capital invested

Capital invested by funds: $142M → $122M (-$20.3M)

18% less repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 40

44% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 9

90% less call options, than puts

Call options by funds: $15K | Put options by funds: $146K

Holders
96
Holders Change
-4
Holders Change %
-4%
% of All Funds
2.77%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
33
Reduced
40
Closed
9
Calls
$15K
Puts
$146K
Net Calls
-$131K
Net Calls Change
-$236K

Top Buyers

Rank Fund Capital Flow
1
NCM
Nantahala Capital Management
Connecticut
+$1.1M
2
Franklin Resources
Franklin Resources
California
+$712K
3
QBFM
QS Batterymarch Financial Management
New York
+$644K
4
BFA
BlackRock Fund Advisors
California
+$390K
5
Citadel Advisors
Citadel Advisors
Florida
+$349K

Top Sellers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
-$2.21M
2
Millennium Management
Millennium Management
New York
-$1.78M
3
BIT
BlackRock Institutional Trust
California
-$1.76M
4
OAM
Oxford Asset Management
United Kingdom
-$1.12M
5
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$1.08M
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of America
26
Bank of America
North Carolina
$653K +$604 +125 +0.1%
SO
27
STRS Ohio
Ohio
$642K – – –
D.E. Shaw & Co
28
D.E. Shaw & Co
New York
$641K -$292K -60,502 -30%
Charles Schwab
29
Charles Schwab
California
$533K +$14.5K +3,000 +3%
GCP
30
GSA Capital Partners
United Kingdom
$530K -$30K -6,204 -5%
Norges Bank
31
Norges Bank
Norway
$491K – – –
AQR Capital Management
32
AQR Capital Management
Connecticut
$486K -$585K -121,100 -53%
CS
33
Credit Suisse
Switzerland
$482K -$22.9K -4,748 -4%
RFC
34
Russell Frank Company
Washington
$478K -$25.4K -5,263 -5%
AllianceBernstein
35
AllianceBernstein
Tennessee
$468K -$20.9K -4,333 -4%
California State Teachers Retirement System (CalSTRS)
36
California State Teachers Retirement System (CalSTRS)
California
$445K – – –
ProShare Advisors
37
ProShare Advisors
Maryland
$434K +$329K +68,020 +248%
American Century Companies
38
American Century Companies
Missouri
$417K +$3.43K +711 +0.8%
GS
39
Gagnon Securities
New York
$361K +$6.01K +1,245 +2%
State Board of Administration of Florida Retirement System
40
State Board of Administration of Florida Retirement System
Florida
$361K +$205K +42,425 +115%
TA
41
Teachers Advisors
New York
$354K – – –
Goldman Sachs
42
Goldman Sachs
New York
$331K -$55.2K -11,419 -14%
FQ
43
First Quadrant
California
$294K – – –
DIA
44
Denver Investment Advisors
Colorado
$285K +$212K +43,971 +235%
Two Sigma Investments
45
Two Sigma Investments
New York
$284K -$311K -64,309 -51%
Swiss National Bank
46
Swiss National Bank
Switzerland
$269K +$35.3K +7,300 +14%
RhumbLine Advisers
47
RhumbLine Advisers
Massachusetts
$238K -$12.7K -2,630 -5%
NFA
48
Nationwide Fund Advisors
Ohio
$236K – – –
CBOA
49
Commonwealth Bank of Australia
Australia
$231K -$35.1K -7,263 -13%
MLICM
50
Metropolitan Life Insurance Company (MetLife)
New York
$221K – – –
1
2
3 4 5

SCLN Hedge Fund Activity: Q1 2014 in Review

96 of the 3,463 institutional investors tracked by Wall St. Rank reported a position in Sciclone Pharmaceuticals Inc (SCLN) for Q1 2014, worth a combined $122M — down 14% from $142M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of SCLN and 5 opened new positions — a net loss of 4 holders — while 40 trimmed existing stakes and 33 added.

The largest buyer was Nantahala Capital Management, adding an estimated $1.1M. The largest seller was JP Morgan Chase, exiting entirely with an estimated $2.21M sold.

  • 96 institutional investors held Sciclone Pharmaceuticals Inc (SCLN) as of Q1 2014, down from 100 in Q4 2013.
  • Funds reported $122M of Sciclone Pharmaceuticals Inc stock for Q1 2014, down 14% quarter-over-quarter.
  • 5 funds opened new Sciclone Pharmaceuticals Inc positions in Q1 2014 and 9 closed out, a net change of -4 holders.
  • The largest Sciclone Pharmaceuticals Inc buyer in Q1 2014 was Nantahala Capital Management, an estimated $1.1M added.
  • The largest Sciclone Pharmaceuticals Inc seller in Q1 2014 was JP Morgan Chase, an estimated $2.21M sold.

Based on aggregated 13F filings for Q1 2014.